Regen Bio provides an update on IND

|By:, SA News Editor

Bio-Matrix Scientific Group (BMSN +70.8%) subsidiary Regen BioPharma provides an update on its follow up on the FDA's issues regarding its HemaXellerate IND. On March 6, 2014 the company submitted a protocol modification, additional details on manufacturing, new data on the therapeutic effects of HemaXellerate I in animal models of diseases similar to aplastic anemia in humans and additional safety data to the FDA.

The agency accepted the clinical protocol and product manufacturing information but requested clarification on the animal safety studies.

On May 9, the company updated the IND and submitted it to the FDA for review.